Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | NOS1 | P29475 | 3/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.59 |
| ▸ | METAP2 | P50579 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12354 | 1.00 | KDM4E (0.59) | KDM4EMAPTNOS1DYRK1AMETAP2 | |
| SCHEMBL13115655 | 0.84 | FGFR1 (0.71) | KDM4EMAPTNOS1DYRK1AMETAP2 | |
| Trifluoroacetic Acid SCHEMBL29803957 | 0.83 | METAP2 (0.51) | KDM4EMAPTNOS1DYRK1AMETAP2 | |
| SCHEMBL29409358 | 0.83 | ROCK2 (0.59) | KDM4EMAPTNOS1DYRK1AMETAP2 | |
| SCHEMBL12872 | 0.83 | ROCK2 (0.59) | KDM4EMAPTNOS1DYRK1AMETAP2 | |
| Bromide SCHEMBL17924434 | 0.81 | ROCK2 (0.57) | KDM4EMAPTNOS1DYRK1AMETAP2 | |
| SCHEMBL8264120 | 0.80 | FGFR1 (0.70) | KDM4EMAPTNOS1DYRK1AMETAP2 | |
| SCHEMBL11575046 | 0.77 | GAA (0.50) | KDM4EMAPTNOS1DYRK1AMETAP2 | |
| SCHEMBL25860940 | 0.77 | KDM1A (0.58) | KDM4EMAPTNOS1DYRK1AMETAP2 | |
| SCHEMBL14349688 | 0.75 | IDO1 (0.42) | KDM4EMAPTMETAP2HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111788183-B | Heterocyclic fused phenyl compounds useful for inhibiting TNIK and medical uses thereof | 韩国化学硏究院 | 2024-02-23 | — | — | CN | claimed |
| EP-3749647-B1 | N-(5-(PHENYL)-1H-PYRAZOL-3-YL)-1H-INDOL-5-AMINE DERIVATIVES AS TNIK INHIBITORS FOR THE TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2023-09-27 | — | — | EP | claimed |
| US-11447469-B2 | Hetero ring-fused phenyl compounds for inhibiting TNIK and medical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-09-20 | — | — | US | claimed |
| US-20210047300-A1 | HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-02-18 | — | — | US | claimed |
| EP-3749647-A1 | HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | Korea Research Institute of Chemical Technology (KR) | 2020-12-16 | — | — | EP | claimed |
| CN-111788183-A | Heterocyclic fused phenyl compounds for inhibiting TNIK and medical uses thereof | 韩国化学硏究院 | 2020-10-16 | — | — | CN | claimed |
| WO-2019156438-A1 | HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2019-08-15 | — | — | WO | claimed |
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| US-20260015351-A1 | METHODS AND COMPOUNDS FOR INHIBITING MKK7 ENZYMES | AXONIS THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2025151594-A1 | FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20250214971-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2025-07-03 | — | — | US | disclosed |
| US-20250115583-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2025-04-10 | — | — | US | disclosed |
| US-20250092023-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2025-03-20 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
| WO-2004037176-A2 | QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004031145-A2 | LACTAM-CONTAINING DIAMINOALKYL, BETA-AMINOACIDS, ALPHA-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2003099276-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003047520-A2 | SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003048081-A2 | GLYCINAMIDES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003026652-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | KDM4E 980/4885MAPT 2426/4885NOS1 1083/4885 |
| US-20250115583-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR1I2 | KDM4E 4539/4885MAPT 4150/4885NOS1 3026/4885 |
| US-20260015351-A1 | METHODS AND COMPOUNDS FOR INHIBITING MKK7 ENZYMES | PRKCSH, MAPK7, PRKCB | KDM4E 1995/4885MAPT 4035/4885NOS1 4056/4885 |
| US-20210047300-A1 | HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | TNNI3K, TNK1, TNIK | KDM4E 1486/4885MAPT 3307/4885NOS1 1976/4885 |
| US-20250092023-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR5A2 | KDM4E 3727/4885MAPT 4749/4885NOS1 3147/4885 |
| US-20250214971-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | KDM4E 3007/4885MAPT 3957/4885NOS1 4171/4885 |
| US-11447469-B2 | Hetero ring-fused phenyl compounds for inhibiting TNIK and medical uses thereof | TNNI3K, TNK1, TNIK | KDM4E 1486/4885MAPT 3307/4885NOS1 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.